NASDAQ: SPTX
Seaport Therapeutics, Inc.CIK 0002042347 · SIC 2834 · Pharmaceutical Preparations
Small by assets
Assets $442M
as of Aug 30, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
10-Q
Filed Aug 3, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Aug 3, 2026
· Period ending Aug 3, 2026
Summary not yet generated.
Partner
Trade SPTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
10-Q
Filed Jun 8, 2026
· Period ending Mar 31, 2026
net income -$25.4M. Seaport Therapeutics debuts with IPO, advancing two neuropsychiatric trials
5 material changes detected. Sign up free to read the summary.
8-K
Filed Jun 8, 2026
· Period ending Jun 8, 2026
Seaport Therapeutics reports Q1 2026 financial results
2 material changes detected. Sign up free to read the summary.
8-K
Filed May 4, 2026
· Period ending May 4, 2026
Seaport Therapeutics completes IPO, Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) with 700M shares
4 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Aug 3, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except share and per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development (including non-cash stock-based compensation expense of $0.9 million and $0.6 million for three months ended June 30, 2026 and 2025, respectively and $1.8 million and $1.1 million for six months ended June 30, 2026 and 2025, respectively) | 24,619 | 13,409 | 46,049 | 23,944 |
| General and administrative (including non-cash stock-based compensation expense of $36.0 million and $1.2 million for three months ended June 30, 2026 and 2025, respectively and $37.6 million and $2.3 million for six months ended June 30, 2026 and 2025, respectively) | 41,189 | 5,061 | 47,302 | 10,711 |
| Total operating expenses | 65,808 | 18,470 | 93,351 | 34,655 |
| Loss from operations | (65,808) | (18,470) | (93,351) | (34,655) |
| Other income (expense), net | ||||
| Interest income, net | 3,257 | 2,976 | 5,390 | 6,076 |
| Research and development tax credit | 236 | 610 | 803 | 610 |
| Other expense, net | (34) | (59) | (80) | (68) |
| Total other income, net | 3,459 | 3,527 | 6,113 | 6,618 |
| Loss before income taxes | (62,349) | (14,943) | (87,238) | (28,037) |
| Income tax provision | 251 | 134 | 770 | 165 |
| Net loss | (62,600) | (15,077) | (88,008) | (28,202) |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustment | 18 | (3) | 33 | (3) |
| Unrealized (loss) gain on available-for-sale securities | (557) | (59) | (809) | 133 |
| Comprehensive loss | (63,139) | (15,139) | (88,784) | (28,072) |
| Net loss per share, basic and diluted | (1.78) | (6.40) | (4.60) | (12.05) |
| Weighted-average common shares outstanding, basic and diluted | 35,236,214 | 2,356,777 | 19,118,049 | 2,340,431 |
Condensed Consolidated Balance Sheets (Unaudited)
(In thousands, except share and per share amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 64,223 | 46,042 |
| Short-term investments | 209,086 | 169,941 |
| Prepaid expenses and other current assets | 8,866 | 7,247 |
| Total current assets | 282,175 | 223,230 |
| Property and equipment, net | 360 | 412 |
| Right-of-use assets operating leases | 4,741 | 4,813 |
| Long-term investments | 153,951 | 17,670 |
| Other non-current assets | 454 | 2,884 |
| Total assets | 441,681 | 249,009 |
| Liabilities, convertible preferred stock and stockholders' equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | 5,705 | 2,007 |
| Related party payable | — | 7 |
| Accrued expenses and other current liabilities | 8,358 | 9,131 |
| Operating lease liability | 1,611 | 1,637 |
| Total current liabilities | 15,674 | 12,782 |
| Operating lease liability, net of current portion | 3,405 | 3,444 |
| Total liabilities | 19,079 | 16,226 |
| Series A-1 convertible preferred stock, par value $0.0001; zero and 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; zero and 40,000,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of zero and $4,000 as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Series A-2 convertible preferred stock, par value $0.0001; zero and 26,342,102 shares authorized as of June 30, 2026 and December 31, 2025, respectively; zero and 26,342,102 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of zero and $100,100 as of June 30, 2026 and December 31, 2025, respectively | — | 99,757 |
| Series B convertible preferred stock, par value $0.0001; zero and 47,578,938 shares authorized as of June 30, 2026 and December 31, 2025, respectively; zero and 47,578,934 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of zero and $226,000 as of June 30, 2026 and December 31, 2025, respectively | — | 225,571 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' deficit | ||
| Undesignated preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized at June 30, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, par value $0.0001; 700,000,000 and 159,070,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 53,530,550 and 2,595,342 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 5 | 1 |
| Additional paid-in capital | 625,189 | 21,262 |
| Accumulated other comprehensive income | (475) | 301 |
| Accumulated deficit | (202,117) | (114,109) |
| Total stockholders' equity (deficit) | 422,602 | (92,545) |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | 441,681 | 249,009 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | (88,008) | (28,202) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 39,432 | 3,375 |
| Depreciation expense | 52 | 77 |
| Amortization of operating lease right-of-use assets | 656 | 592 |
| Net amortization of premiums and discounts on investments | (582) | (2,019) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (433) | (5,494) |
| Other non-current assets | - | (1,191) |
| Accounts payable | 3,690 | (2,604) |
| Related party payable | (7) | (283) |
| Accrued expenses and other current liabilities | (461) | 709 |
| Operating lease liability | (652) | (490) |
| Net cash used in operating activities | (46,313) | (35,530) |
| Investing activities | ||
| Purchases of investments | (300,652) | (304,171) |
| Proceeds from maturities of investments | 125,000 | 77,500 |
| Purchases of property and equipment | — | (323) |
| Net cash used in investing activities | (175,652) | (226,994) |
| Financing activities | ||
| Proceeds from initial public offering, net of underwriting discounts and commissions and deferred offering costs | 239,338 | — |
| Proceeds from exercise of stock options | 807 | — |
| Net cash provided by financing activities | 240,145 | — |
| Effect of exchange rates on cash and cash equivalents | 1 | — |
| Net increase (decrease) in cash and cash equivalents | 18,181 | (262,524) |
| Cash, cash equivalents, and restricted cash, beginning of period | 46,496 | 309,553 |
| Cash, cash equivalents, and restricted cash, end of period | 64,677 | 47,029 |
| Supplemental disclosure of non-cash operating, financing, and investing information: | ||
| Operating lease right-of-use assets obtained in exchange for lease liabilities | 584 | 1,114 |
| Deferred offering costs included in accounts payable and accrued expenses | 97 | — |
Amounts as printed on the EDGAR/iXBRL face — (In thousands, except share and per share amounts); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗